Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.40 |
| ▸ | DPP4 | P27487 | 3/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.38 |
| ▸ | CD38 | P28907 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.36 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21526029 | 0.99 | SMN1; SMN2 (0.42) | SMN1; SMN2HTTMDM2EPHX1DPP4 | |
| Hydrochloric Acid SCHEMBL21526027 | 0.99 | SMN1; SMN2 (0.42) | SMN1; SMN2HTTMDM2EPHX1DPP4 | |
| SCHEMBL21548806 | 0.83 | SMN1; SMN2 (0.44) | SMN1; SMN2HTTMDM2DPP4DPP8 | |
| SCHEMBL20356667 | 0.82 | SMN1; SMN2 (0.54) | SMN1; SMN2HTTDPP4DPP8P2RX7 | |
| SCHEMBL21526073 | 0.82 | SMN1; SMN2 (0.44) | SMN1; SMN2HTTMDM2DPP4DPP8 | |
| SCHEMBL21548809 | 0.81 | SMN1; SMN2 (0.43) | SMN1; SMN2HTTMDM2DPP4DPP8 | |
| Hydrochloric Acid SCHEMBL21526024 | 0.81 | SMN1; SMN2 (0.43) | SMN1; SMN2HTTMDM2DPP4DPP8 | |
| Hydrochloric Acid SCHEMBL21526127 | 0.81 | SMN1; SMN2 (0.43) | SMN1; SMN2HTTMDM2DPP4DPP8 | |
| SCHEMBL20356749 | 0.80 | SMN1; SMN2 (0.43) | SMN1; SMN2HTTP2RX7CD38 | |
| SCHEMBL21526141 | 0.79 | SMN1; SMN2 (0.49) | SMN1; SMN2HTTEPHX1DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3564216-B1 | PYRIMIDINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2021-10-27 | — | — | EP | disclosed |
| US-11034659-B2 | Pyrimidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-15 | — | — | US | disclosed |
| US-20200172494-A1 | PYRIMIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-06-04 | — | — | US | disclosed |
| EP-3564216-A1 | PYRIMIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-11-06 | — | — | EP | disclosed |
| WO-2018124000-A1 | PYRIMIDINE DERIVATIVE | 第一三共株式会社 | 2018-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034659-B2 | Pyrimidine derivative | GPR39, CFTR, TMEM109 | SMN1; SMN2 2983/4885HTT 3973/4885MDM2 4223/4885 |
| US-20200172494-A1 | PYRIMIDINE DERIVATIVE | GPR39, CFTR, TMEM109 | SMN1; SMN2 2983/4885HTT 3973/4885MDM2 4223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.